Abstract
Information on human genetic variance is only just beginning to be used in drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Putney, S.D. et al. Nature 302, 718–721 (1983).
Cooper, T.A. et al. Science 226, 979–982 (1984).
Zipkin, I. et al. BioCentury Oct. 20, A5 (1997).
Reddy D.S. et al. Methods Find. Exp. Clin. Pharmacol. 18, 261– 271 (1996).
Jerkovic, R. et al. Cell Struct. Funct. 22, 147– 153 (1997).
Olschwang, S. et al. Proc. Natl. Acad. Sci. USA 94, 12122– 12127(1997).
Persidis, A. Nat. Biotechnol. 15, 1409–1411 (1997).
Rioux, P.P. Am. J. Health Syst. Pharm. 57, 887– 898 (2000).
McCarthy, J.J. & Hilfiker, R. Nat. Biotechnol. 18 , 505–508 (2000).
Issa, A.M. Trends Pharmacol. Sci. 21, 247–249 (2000).
Rights and permissions
About this article
Cite this article
Pharmacogenomics. Nat Biotechnol 18 (Suppl 10), IT40–IT42 (2000). https://doi.org/10.1038/80079
Issue Date:
DOI: https://doi.org/10.1038/80079
This article is cited by
-
Ethical perspectives on pharmacogenomic profiling in the drug development process
Nature Reviews Drug Discovery (2002)